IP Library Granted Patent US 8,227,457
Granted Patent B2
US 8,227,457 · App. 13/276,810 · Granted Jul 24, 2012

Method for treatment of diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,457
App. No.
13/276,810
Granted
Jul 24, 2012
Kind
B2
Abstract

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.

Claims (9)

1. A method of treating macular edema in a human comprising orally administering to the human a vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof, wherein the hyperpermeability-inhibiting amount is from 1 mg to 100 mg per day.

2. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount is from 10 mg to 90 mg per day.

3. The method of claim 1 wherein the macular edema is caused by a vascular occlusion, a post-intraocular surgery, a uveitis or a retinitis.

4. The method of claim 1 wherein the macular edema is diabetic macular edema.

5. The method of claim 1 wherein the human has diabetic retinopathy.

6. The method of claim 5 wherein the diabetic retinopathy is nonproliferative diabetic retinopathy.

7. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount of the danazol or pharmaceutically acceptable salt thereof is administered to the human at the appearance of one or more early signs of, or a predisposition to develop, macular edema.

8. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount of the danazol or pharmaceutically acceptable salt thereof is administered to the human immediately upon diagnosis of macular edema.

9. The method of claim 1 wherein the macular edema is from vascular-hyperpermeability of a continuous endothelium found in, or around, a retina.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2013
From: DMI ACQUISITION CORP.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 031305/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2012
From: BAR-OR, DAVID
To: DMI ACQUISITION CORP.
Reel/Frame 029315/0802 →